179026-34-7

Upstream product

• 3251-69-2 2-(1H-imidazol-5-yl)acetic acid hydrochloride 
• 17201-43-3 4-cyanobenzyl bromide 
• 145133-11-5 methyl [1-(triphenylmethyl)-1H-imidazol-4-yl]acetate 

Downstream Products

• 221266-52-0 1-(4-cyanophenylmethyl)-5-imidazole acid hydrochloride 
• 198646-94-5 N-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}-4-(3-methylphenyl)-4-hydroxy piperidine 
• 179026-12-1 2(S)-<2-[(2(S)-<2-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]acetylamino>-3(S)-methylpentyl)naphthalen-1-ylmethylamino]acetylamino>-4-(methylsulfanyl)butyric acid methyl ester 
• 245062-21-9 2(S)-<2-[(2(S)-<2-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]acetylamino>-3(S)-methylpentyl)naphthalen-1-ylmethylamino]acetylamino>-4-methylpentanoic acid methyl ester 
• 186202-63-1 methanesulfonic acid 2-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]ethyl ester 
• 186202-60-8 4-[5-(2-hydroxyethyl)imidazol-1-ylmethyl]benzonitrile 
• 179026-35-8 1-(4-cyanophenylmethyl)-1H-imidazol-5-ylacetic acid 

Relevant academic research and scientific papers

Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase

Inhibitors of farnesyl protein transferase (FPTase) based upon a pseudotripeptide template are described that comprise an imidazole group substituted with a hydrophobic substituent. (1,5)-Disubstitution of the imidazole group is shown to be the optimal ar

Prenyl transferase inhibitors

A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R23); and the remaining substituents are as defined in the disclosure.

Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors

PCT No. PCT/US97/06257 Sec. 371 Date Oct. 2, 1998 Sec. 102(e) Date Oct. 2, 1998 PCT Filed Apr. 1, 1997 PCT Pub. No. WO97/36876 PCT Pub. Date Oct. 9, 1997The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Arylheteroaryl inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit famesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting famesyl-protein transferase and the famesyl of the oncogene protein Ras.

Biheteroaryl inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production

BIHETEROARYL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras